<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="602">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222922</url>
  </required_header>
  <id_info>
    <org_study_id>B7661001</org_study_id>
    <secondary_id>2014-003296-36</secondary_id>
    <nct_id>NCT02222922</nct_id>
  </id_info>
  <brief_title>A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A First-In-Human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of PF-06647020 In Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients
      with advanced solid tumors in order to determine the maximum tolerated dose and select the
      recommended Phase 2 dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) {Part1}</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>First cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>Days 1, 15, 21, and every 21 days thereafter up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with the presence of anti-PF-06647020 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response (Part 1)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with objective response based on assessment of response rate (RR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response (Part 2)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of participants with objective response based on assessment of overall response rate (ORR) and progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06380101 when PF-06647020 is combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06647020 when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>CL is a quantitative measure of the rate at which a drug substance is removed from the body.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution (Vd) for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Decay Half-Life (t1/2) for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax) for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for hu6M024 mAb when combined with fluconazole</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-06647020</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug infused over 60 minutes once every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-drug interaction</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06647020 combined with fluconazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020</intervention_name>
    <description>Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.</description>
    <arm_group_label>PF-06647020</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020</intervention_name>
    <description>Part 2: Patients with triple negative breast cancer (unselected for PTK7 expression) or non small cell lung cancer (pre-selected with moderate to high PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.</description>
    <arm_group_label>PF-06647020</arm_group_label>
    <arm_group_label>Drug-drug interaction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>combination drug used for drug-drug interaction sub-study</description>
    <arm_group_label>Drug-drug interaction</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of solid tumor that is advanced/metastatic and resistant to standard
             therapy or for whom no standard therapy is available

          -  Performance Status of 0 or 1

          -  Adequate bone marrow, kidney, and liver function

          -  Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
             non small cell lung cancer patients

        Exclusion Criteria:

          -  Brain metastases requiring steroids

          -  Drug-drug interaction includes advanced metastatic breast cancer, ovarian cancer, or
             non small cell lung cancer patients

          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
             study treatment start

          -  Active and clinically significant bacterial, fungal, or viral infection
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center Pharmacy</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Translational Research Unit (CTRU)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center (Drug Shiment Only)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7661001&amp;StudyName=A%20Study%20Of%20PF-06647020%20For%20Adult%20Patients%20With%20Advanced%20Solid%20Tumors%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2016</verification_date>
  <lastchanged_date>June 1, 2016</lastchanged_date>
  <firstreceived_date>August 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADC</keyword>
  <keyword>PF-06647020</keyword>
  <keyword>solid tumors</keyword>
  <keyword>tumors</keyword>
  <keyword>neoplasm metastasis</keyword>
  <keyword>TNBC</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>advanced metastatic breast cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>OVCA</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
